Three studies find IDH enzyme mutations may alter activity leading to growth of cancer tumors

February 16, 2012 by Bob Yirka report

(Medical Xpress) -- Three research teams have published papers in Nature, that together offer evidence suggesting that isocitrate dehydrogenase (IDH) enzyme mutations may play a role in altering activity that could have an impact on whether or not cancerous tumors begin to grow.

IDHs are enzymes that are part of the chemical reactions that lead to energy production in cells. Mutations that occur within such enzymes have been linked to many kinds of cancers, including gliomas, which is cancer that starts in in the brain. One of the mysterious of how get their start though is the process by which such mutations actually contribute to tumor growth. In the three new studies, researchers find that mutations in IDH enzymes can interfere with the switching on and off processes that can lead to a problem with .

In one of the studies, a group led by Timothy Chan demonstrated that mutations of IDH1 led to alterations of DNA in glial cells, which were the same changes as were seen in some types of glioma, which seem to indicate that there is a likely link. As part of that research the team showed that mutations in the enzyme that regulate how much are deposited on DNA can create changes in the process that is involved in the switching on and off of gene expressions across an entire genome.

In another of the papers, Craig Thompson and fellow researchers found that the expression of mutant DNA produced the metabolite 2-hydroxyglutarate (2HG) which is known to interfere with of histones leading to cell differentiation, which could lead to tumors.

And finally, in the third study, William Kaelin and colleagues examined different possibilities in exploring how 2HG accumulating in cells helps induce cell growth by interrupting the actions of proteins that are known to suppress tumors.

In cancer research, both lack of cell differentiation and are clear early indicators of tumor growth. Studies such as these make it clear that mutations in IDH enzymes are almost certainly involved in preventing them from functioning properly leading to the growth of , thus the development of pharmaceutical therapies that could prevent such mutations may lead to ways to prevent tumors from starting.

Explore further: Two-faced leukemia?

More information: The three Nature papers are:

Related Stories

Two-faced leukemia?

December 12, 2011

One kind of leukemia sometimes masquerades as another, according to a study published online this week in the Journal of Experimental Medicine.

Seeing what's inside a tumor

January 12, 2012

Gliomas, the most common types of brain tumor, are also among the deadliest cancers: Their mortality rate is nearly 100 percent, in part because there are very few treatments available. 

Novel gene mutations associated with bile duct cancer

January 18, 2012

Investigators at the Massachusetts General Hospital (MGH) Cancer Center have identified a new genetic signature associated with bile duct cancer, a usually deadly tumor for which effective treatment currently is limited. ...

Recommended for you

Functional human liver cells grown in the lab

November 26, 2015

In new research appearing in the prestigious journal Nature Biotechnology, an international research team led by The Hebrew University of Jerusalem describes a new technique for growing human hepatocytes in the laboratory. ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.